This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrinology
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Bluesky (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:58827/feed
ISSN 2327-2236
Oncology
Vol. 3, Issue 2, 2016October 21, 2015 EDT

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo,
spaincost-utilitycost-effectivenesseribulinher2-negativemetastatic breast cancer
Copyright Logoccby-4.0 • https://doi.org/10.36469/9834
Photo by Ken Treloar on Unsplash

Articles in Vol. 3, Issue 2, 2016

Vol. 3, Issue 2, 2016
  • Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
    Gabriel TremblayUnnati MajethiaIlias KontoudisJesús De Rosendo
  • Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
    Tao GuNeel ShahGaurav DeshpandeDerek H. TangDebra F. EisenbergDavid J. Harrison
  • A Characterisation and Profiling of District Health Indicators in Zimbabwe: An Application of Principal Component Analysis in a Data Limited Setting
    Shepherd ShamuSimbarashe RusakanikoCharles Hongoro
  • How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines
    Lindsay GovanOlivia WuRobert LindsayAndrew Briggs
  • Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
    Santiago GrauCarlos SolanoCarol García-VidalIsidro JarqueJon A. BarruetaCarmen PeralIrene RodríguezDarío Rubio-RodríguezCarlos Rubio-Terrés
  • Montelukast Use and Patterns of Ambulatory Care among Asian versus Non-Asian Adult Patients with Asthma and/or Allergic Rhinitis in the United States
    Joseph VaseyShalini BaggaHuan HuangTongsheng WangDavid Thompson
  • Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
    November McGarveyHairong Xu
JHEOR
1.
Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy. JHEOR. 2015;3(2):180-193. doi:10.36469/9834
Save article as...▾

View more stats

Powered by Scholastica, the modern academic journal management system